Search
Search
Invitrogen
{{$productOrderCtrl.translations['antibody.pdp.commerceCard.promotion.promotions']}}
{{$productOrderCtrl.translations['antibody.pdp.commerceCard.promotion.viewpromo']}}
{{$productOrderCtrl.translations['antibody.pdp.commerceCard.promotion.promocode']}}: {{promo.promoCode}} {{promo.promoTitle}} {{promo.promoDescription}}. {{$productOrderCtrl.translations['antibody.pdp.commerceCard.promotion.learnmore']}}
OPA1-03075 detects cJun N-terminal kinase (JNK) from human and rat tissues and cells.
OPA1-03075 has been successfully used in Western blot procedures. By Western blot, this antibody detects an ~49 kDa protein and an ~55 kDa protein representing JNK1 and 2, respectively, from platelet-derived growth factor (PDGF) treated NIH-3T3 cell extract.
OPA1-03075 immunizing phosphopeptide was derived from human JNK 1 and 2 that contains threonine 183 and tyrosine 185. This region is conserved among many species including mouse, rat, chicken, nematode, fruit fly, and in JNK3.
C-Jun N-terminal Kinase (JNK) is also known as Mitogen-activated protein kinase (MAPK8). It belongs to the MAPK superfamily of stress-activated protein kinases. MAPKs are Serine-threonine protein kinases that are activated in response to a variety of extracellular stimuli, and mediate signal transduction from the cell surface to the nucleus. JNK is involved in a wide variety of cellular processes such as proliferation, differentiation, transcription regulation and development. JNK pathways are activated by stress and inflammatory signals. JNK is expressed as ten different isoforms due to differential mRNA splicing. The predominant forms are JNK1 and JNK2.
仅用于科研。不用于诊断过程。未经明确授权不得转售。